# Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients

> **NCT02683083** · PHASE1 · COMPLETED · sponsor: **Precirix** · enrollment: 9 (actual)

## Conditions studied

- Healthy Volunteers
- Breast Cancer

## Interventions

- **BIOLOGICAL:** [131I]-SGMIB Anti-HER2 VHH1

## Key facts

- **NCT ID:** NCT02683083
- **Lead sponsor:** Precirix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2018-02-05
- **Final completion:** 2018-02-05
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02683083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02683083, "Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02683083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*